Skin Substitute Access and Payment Reform Act of 2025
- Bill Number
- S. 2561
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-31: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-10-29T11:03:14Z
AI-Generated Summary
Purpose
The Skin Substitute Access and Payment Reform Act of 2025 aims to update Medicare payment and coverage rules for skin substitute products—advanced therapies used to treat chronic wounds like diabetic foot ulcers. It seeks to standardize payments, reduce costs, and ensure fair access to these treatments, which help improve healing and prevent amputations for Medicare beneficiaries, while addressing rising expenditures.
Key Provisions
- Payment System Reform: Starting January 1, 2026, Medicare payments for skin substitute products will use a single, volume-weighted average payment limit based on 2023 pricing and usage data from the Average Sales Price (ASP) Pricing File and Part B claims. This amount will be updated annually from 2027 onward using the Consumer Price Index for All Urban Consumers (CPI-U) to account for inflation.
- Definition of Skin Substitute Products: These are cellular, biological, or synthetic materials applied to wounds to stay in place and promote healing. They must be approved, cleared, or authorized by the FDA under specific pathways (e.g., 510(k) clearance or biologics licensing). Exclusions include temporary wound dressings, liquids/gels/powders, and certain drugs or vaccines.
- Billing and Coverage Rules:
- A new unified billing and payment code will be created for all skin substitute products by January 1, 2026.
- Coverage determinations will treat all products similarly as "reasonable and necessary" under Medicare rules, unless the Secretary of Health and Human Services finds evidence of safety issues like contamination or serious adverse reactions.
- Denials of coverage cannot be based solely on clinical evidence analysis.
- Manufacturers are exempt from reporting average sales prices (ASP) for these products.
- Congressional Findings: The bill highlights the clinical benefits of skin substitutes, variations in product types (human, animal, or synthetic), provider expertise in selection, CMS pricing challenges, and the need to curb cost increases without undermining treatment efficacy.
Significant Changes to Existing Law
- Amends Section 1847A of the Social Security Act (which governs Medicare Part B drug payments) by adding skin substitute products as a new payment category, replacing variable pricing with a fixed, averaged limit to eliminate incentives for higher-cost products.
- Introduces uniform coverage criteria, preventing differentiated treatment based on product type or clinical studies alone, which contrasts with current practices that allow variability and have led to payment uncertainties.
- Shifts from ongoing ASP reporting and quarterly updates to a static base year (2023) with CPI adjustments, aiming to stabilize costs after significant expenditure rises in 2024 and 2025.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) will face administrative changes, including creating a new billing code and using historical data for payments, potentially reducing overall Medicare spending on these products while simplifying processing.
- On Citizens: Medicare beneficiaries (over 10.5 million annually needing wound care) may gain more consistent access to treatments, improving health outcomes like faster healing and fewer amputations, though payment caps could limit provider choices if products exceed the average.
- On International Relations: Minimal direct impact, as the bill focuses on domestic Medicare policy; however, it could indirectly affect U.S. manufacturers of imported skin substitutes by standardizing payments.
Main Stakeholders Affected
- Medicare Beneficiaries: Primary users of wound treatments, benefiting from cost containment and assured coverage.
- Healthcare Providers: Doctors and wound care specialists who select products; they gain flexibility in choices without coverage denials based on evidence alone.
- Manufacturers and Suppliers: Companies producing skin substitutes (human tissue, animal-derived, or synthetic); they face payment limits and no ASP reporting, which may pressure pricing but ensure market stability.
- CMS and HHS: Responsible for implementation, data analysis, and safety monitoring.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare's authority under Section 1862(a)(1)(A) for "reasonable and necessary" determinations by mandating uniform criteria and limiting denials, potentially reducing litigation over coverage disparities. The exemption from ASP reporting simplifies compliance but may require FDA coordination for product approvals.
- Constitutional: No direct challenges; aligns with Congress's spending power under Article I, Section 8, by reforming entitlement programs without infringing on due process or equal protection.
- Political: Addresses fiscal concerns amid rising Medicare costs, promoting bipartisanship on healthcare efficiency (introduced by Sen. Cassidy, R-LA). It balances innovation incentives with cost control, but could spark debate over limiting provider discretion or favoring certain product types.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Hassan, Margaret Wood [D-NH], Sen. Booker, Cory A. [D-NJ]
Recent Actions
- 2025-07-31: Read twice and referred to the Committee on Finance.
- 2025-07-31: Introduced in Senate
Bill Versions
- Skin Substitute Access and Payment Reform Act of 2025 — issued 2025-07-31 — PDF (8 pages)